SCHEMBL10003392

SCHEMBL10003392

Cc1nc2c(nc1N(C)C(=O)c1ccccc1)c(OC(C)C)c(C(=O)O)n2C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.33
▸ ABCB1 P08183 2/20 0.32
▸ ADORA3 P0DMS8 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ CASP3 P42574 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ SENP8 Q96LD8 1/20 0.32
▸ SENP7 Q9BQF6 1/20 0.32
▸ SENP6 Q9GZR1 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ KMT2A Q03164 3/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ BRPF1 P55201 1/20 0.31
▸ BCL2 P10415 1/20 0.31
▸ MDM2 Q00987 1/20 0.31
▸ MCL1 Q07820 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003981 0.90 MAPK1 (0.38) ADORA3NPC1LMNATP53RAB9A
SCHEMBL10003530 0.80 SMO (0.42) SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1
SCHEMBL10003130 0.78 BCL2 (0.38) ADORA3TP53SMN1; SMN2ALDH1A1KMT2A
SCHEMBL10003360 0.70 CYP1A2 (0.47) ADORA3NPC1LMNATP53RAB9A
SCHEMBL10003735 0.69 HTT (0.45) ADORA3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10004729 0.67 HKDC1 (0.53) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL10003034 0.66 HTT (0.44) ADORA3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10004170 0.66 USP2 (0.37) ADORA3NPC1TP53RAB9AUSP2
SCHEMBL10004654 0.65 GRIA2 (0.37) ADORA3BCL2MDM2MCL1
SCHEMBL10003648 0.65 GABRA2 (0.39) ALDH1A1KDM4EBCL2MDM2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH PPARG 1436/4885ABCB1 562/4885ADORA3 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback